Zuowei Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Zuowei Wang has a total of 149 co-authors. Here are the top co-authors by number of shared publications:
- Yiru Fang
Department of Psychiatry & Affective Disorders Center, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
6 shared publications - Jun Chen
Clinical Research Center & Division of Mood Disorders, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China
3 shared publications - Raymond W. Lam
University of British Columbia
3 shared publications - Xin Yu
Peking University Sixth Hospital, Peking University Institute of Mental Health, NHC Key Laboratory of Mental Health (Peking University), National Clinical Research Center for Mental Disorders (Peking University Sixth Hospital), Beijing, 100191, China
3 shared publications - Guoqing Zhao
Department of Psychology, Shandong Provincial Hospital Affiliated to Shandong First Medical University
2 shared publications Han Rong
Shenzhen Kangning Hospital Shenzhen Mental Health Center Shenzhen China
2 shared publications
Latest Publications
- 9 September 2026
- Published by Wiley in Bipolar Disorders
- Vol. 28 (7) , e70180
Association Between Lithium Use and Suicide‐Related Behaviors in Bipolar Disorder: A Multicenter Study
Background: Lithium has long been associated with reduced suicide risk in bipolar disorder; however, evidence from real‐world clinical populations remains susceptible to confounding, and the behavioral correlates related to this association are not well characterized. Methods: In this multicenter cross‐sectional study, 616 individuals aged 12–45 years with bipolar disorder were recruited from 14 psychiatric centers, of whom 585 had complete data for the present analyses. Lithium exposure within the past year was determined from clinical records. The primary outcome was a composite of suicide‐related behaviors, including suicidal ideation, suicide attempts, and non‐suicidal self‐injury. A pre‐specified analytical framework was applied, with multivariable logistic regression as the primary analysis and propensity score matching (PSM) as the principal approach to improve covariate balance. Regression‐based decomposition analyses were conducted to examine whether aggression was statistically associated with the exposure‐outcome relationship, and restricted cubic spline models were used to characterize the dose–response association between aggression and suicide‐related behaviors. Robustness analyses included inverse probability of treatment weighting (IPTW), alternative matching specifications, E ‐value analyses, cluster‐robust standard errors, and exploratory age‐stratified analyses. Results: Lithium exposure was associated with lower odds of suicide‐related behaviors in both the fully adjusted model (OR = 0.55, 95% CI: 0.34–0.89) and the propensity score‐matched sample (OR = 0.53, 95% CI: 0.33–0.86). Higher aggression scores were linearly associated with increased suicide‐related risk. Exploratory regression‐based decomposition analyses indicated that approximately 20.93% of the observed lithium‐outcome association was statistically accounted for by aggression. Results from robustness analyses were directionally consistent with the primary findings. Conclusions: In this multicenter clinical sample, lithium exposure was consistently associated with lower odds of suicide‐related behaviors across multiple analytic approaches. Aggression was independently associated with suicide‐related risk and statistically accounted for part of the observed association between lithium exposure and suicide‐related outcomes. However, causal inference is limited by the cross‐sectional design, and residual confounding—particularly confounding by indication—remains a key concern. Prospective longitudinal studies are required to clarify temporal relationships and disentangle treatment effects from selection processes.
- 9 September 2026
- Published by Wiley in Bipolar Disorders
- Vol. 28 (7) , e70180
Association Between Lithium Use and Suicide‐Related Behaviors in Bipolar Disorder: A Multicenter Study
Background: Lithium has long been associated with reduced suicide risk in bipolar disorder; however, evidence from real‐world clinical populations remains susceptible to confounding, and the behavioral correlates related to this association are not well characterized. Methods: In this multicenter cross‐sectional study, 616 individuals aged 12–45 years with bipolar disorder were recruited from 14 psychiatric centers, of whom 585 had complete data for the present analyses. Lithium exposure within the past year was determined from clinical records. The primary outcome was a composite of suicide‐related behaviors, including suicidal ideation, suicide attempts, and non‐suicidal self‐injury. A pre‐specified analytical framework was applied, with multivariable logistic regression as the primary analysis and propensity score matching (PSM) as the principal approach to improve covariate balance. Regression‐based decomposition analyses were conducted to examine whether aggression was statistically associated with the exposure‐outcome relationship, and restricted cubic spline models were used to characterize the dose–response association between aggression and suicide‐related behaviors. Robustness analyses included inverse probability of treatment weighting (IPTW), alternative matching specifications, E ‐value analyses, cluster‐robust standard errors, and exploratory age‐stratified analyses. Results: Lithium exposure was associated with lower odds of suicide‐related behaviors in both the fully adjusted model (OR = 0.55, 95% CI: 0.34–0.89) and the propensity score‐matched sample (OR = 0.53, 95% CI: 0.33–0.86). Higher aggression scores were linearly associated with increased suicide‐related risk. Exploratory regression‐based decomposition analyses indicated that approximately 20.93% of the observed lithium‐outcome association was statistically accounted for by aggression. Results from robustness analyses were directionally consistent with the primary findings. Conclusions: In this multicenter clinical sample, lithium exposure was consistently associated with lower odds of suicide‐related behaviors across multiple analytic approaches. Aggression was independently associated with suicide‐related risk and statistically accounted for part of the observed association between lithium exposure and suicide‐related outcomes. However, causal inference is limited by the cross‐sectional design, and residual confounding—particularly confounding by indication—remains a key concern. Prospective longitudinal studies are required to clarify temporal relationships and disentangle treatment effects from selection processes.
- 19 June 2026
- Published by Elsevier in Psychiatry Research
- Vol. 364, 117301
Antidepressant use and worsening of non-suicidal self-injury and suicidality in bipolar disorder: A multicenter retrospective cohort study
- 19 June 2026
- Published by Elsevier in Psychiatry Research
- Vol. 364, 117301
Antidepressant use and worsening of non-suicidal self-injury and suicidality in bipolar disorder: A multicenter retrospective cohort study
- Open Access
- 7 June 2026
- Published by Wiley in International Journal of Methods in Psychiatric Research
- Vol. 35 (2) , e70082
Social and Clinical Factors Associated With Antipsychotic Medication Discontinuation in Patients With Schizophrenia
Objectives: This study aims to identify social and clinical factors associated with antipsychotic medication discontinuation in patients with schizophrenia. Methods: This cross‐sectional case‐control study comprised 111 schizophrenia patients, including 55 who discontinued medication on their own initiative and 56 matched continuous‐treatment patients. Assessed factors covered demographics, clinical profiles, and scores from the Positive and Negative Syndrome Scale (PANSS), the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS), and the Personal and Social Performance (PSP) scale. Results: Patients in the discontinuation group demonstrated significantly higher employment rates ( χ 2 = 24.514, p < 0.001) and marriage rates ( χ 2 = 14.970, p = 0.002) compared to those in the continuous treatment group. The continuous treatment group had more episodes ( p < 0.001) and severe symptoms (PANSS, p < 0.001) with lower cognitive (RBANS, p = 0.001) and social functioning scores (PSP, p < 0.001) compared to the discontinuation group. Regression analysis revealed that fewer episodes ( β = 2.799, p = 0.018) and lower PANSS negative symptom scores ( β = 0.533, p = 0.011) were associated with a greater likelihood of medication discontinuation. Conclusion: The discontinuation group exhibited milder schizophrenia symptoms and higher social functioning than the continuation group. Furthermore, patients with fewer episodes and milder negative symptoms were more likely to discontinue medication.
- 7 June 2026
- Published by Wiley in International Journal of Methods in Psychiatric Research
- Vol. 35 (2) , e70082
Open AccessSocial and Clinical Factors Associated With Antipsychotic Medication Discontinuation in Patients With Schizophrenia
Objectives: This study aims to identify social and clinical factors associated with antipsychotic medication discontinuation in patients with schizophrenia. Methods: This cross‐sectional case‐control study comprised 111 schizophrenia patients, including 55 who discontinued medication on their own initiative and 56 matched continuous‐treatment patients. Assessed factors covered demographics, clinical profiles, and scores from the Positive and Negative Syndrome Scale (PANSS), the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS), and the Personal and Social Performance (PSP) scale. Results: Patients in the discontinuation group demonstrated significantly higher employment rates ( χ 2 = 24.514, p < 0.001) and marriage rates ( χ 2 = 14.970, p = 0.002) compared to those in the continuous treatment group. The continuous treatment group had more episodes ( p < 0.001) and severe symptoms (PANSS, p < 0.001) with lower cognitive (RBANS, p = 0.001) and social functioning scores (PSP, p < 0.001) compared to the discontinuation group. Regression analysis revealed that fewer episodes ( β = 2.799, p = 0.018) and lower PANSS negative symptom scores ( β = 0.533, p = 0.011) were associated with a greater likelihood of medication discontinuation. Conclusion: The discontinuation group exhibited milder schizophrenia symptoms and higher social functioning than the continuation group. Furthermore, patients with fewer episodes and milder negative symptoms were more likely to discontinue medication.
- 31 March 2026
- Published by Elsevier in Psychiatry Research
- Vol. 361, 117131
Comparison of demographic and clinical features in adolescent-onset vs. adult-onset bipolar disorder an analysis of BIPAS Phase II data
- 31 March 2026
- Published by Elsevier in Psychiatry Research
- Vol. 361, 117131
Comparison of demographic and clinical features in adolescent-onset vs. adult-onset bipolar disorder an analysis of BIPAS Phase II data
- Open Access
- 1 October 2025
- Published by Taylor & Francis in Neuropsychiatric Disease and Treatment
- Vol. ume 21, 2279-2291
Efficacy and Safety of Remote Ischemic Conditioning for Depression Insufficiently Responsive to Antidepressant: A Randomized Controlled Trial
Background: Physical therapies are recommended for individuals who are insufficiently responsive to pharmacotherapy and psychotherapy. But most physical therapy needs to be done in a hospital, so finding a physical therapy that can be done at home is very meaningful. This study intends to explore the efficacy and safety of remote ischemic preconditioning (RIPC) as an add-on therapy for depression. Methods: A total of 60 major depressive disorder patients with inadequate response to escitalopram in this study were randomly assigned to sham or active RIPC group. The clinical symptoms, side-effects and physical examination were evaluated and recorded once every 2 weeks until the end of 8th week. The clinical symptoms were evaluated using the 16-item Quick Inventory of Depressive Symptomatology (Self-Report) (QIDS-16-SR) and the Generalized Anxiety Disorder 7-item scale (GAD-7). Side-effects included skin ecchymosis, risk of manic episodes, and RIPC-related serious adverse events. Physical examination included heart rate and blood pressure. Results: No significant difference in QIDS-16-SR and GAD-7 scores between the two groups was found at baseline, week 2, week 4, week 6 and week 8 (P > 0.05). There were no significant differences in heart rate and blood pressure (including systolic and diastolic blood pressure) at any time point between the active group and the sham group (P > 0.05). There were no manic or hypomanic episodes associated with the study. Conclusion: For depression patients with poor response to antidepressant therapy, the efficacy of RIPC as adjuvant therapy was not observed in this study. In general, RIPC adjuvant therapy is relatively safe, and has no significant effect on cardiovascular system, nor does it increase the risk of manic episode.
- 1 October 2025
- Published by Taylor & Francis in Neuropsychiatric Disease and Treatment
- Vol. ume 21, 2279-2291
Open AccessEfficacy and Safety of Remote Ischemic Conditioning for Depression Insufficiently Responsive to Antidepressant: A Randomized Controlled Trial
Background: Physical therapies are recommended for individuals who are insufficiently responsive to pharmacotherapy and psychotherapy. But most physical therapy needs to be done in a hospital, so finding a physical therapy that can be done at home is very meaningful. This study intends to explore the efficacy and safety of remote ischemic preconditioning (RIPC) as an add-on therapy for depression. Methods: A total of 60 major depressive disorder patients with inadequate response to escitalopram in this study were randomly assigned to sham or active RIPC group. The clinical symptoms, side-effects and physical examination were evaluated and recorded once every 2 weeks until the end of 8th week. The clinical symptoms were evaluated using the 16-item Quick Inventory of Depressive Symptomatology (Self-Report) (QIDS-16-SR) and the Generalized Anxiety Disorder 7-item scale (GAD-7). Side-effects included skin ecchymosis, risk of manic episodes, and RIPC-related serious adverse events. Physical examination included heart rate and blood pressure. Results: No significant difference in QIDS-16-SR and GAD-7 scores between the two groups was found at baseline, week 2, week 4, week 6 and week 8 (P > 0.05). There were no significant differences in heart rate and blood pressure (including systolic and diastolic blood pressure) at any time point between the active group and the sham group (P > 0.05). There were no manic or hypomanic episodes associated with the study. Conclusion: For depression patients with poor response to antidepressant therapy, the efficacy of RIPC as adjuvant therapy was not observed in this study. In general, RIPC adjuvant therapy is relatively safe, and has no significant effect on cardiovascular system, nor does it increase the risk of manic episode.
- Open Access
- 14 March 2025
- Published by Elsevier in Journal of Pharmaceutical Analysis
- Vol. 15 (10) , 101264
Biomarkers of bipolar disorder in omics and neuroimaging
- 14 March 2025
- Published by Elsevier in Journal of Pharmaceutical Analysis
- Vol. 15 (10) , 101264
Open AccessBiomarkers of bipolar disorder in omics and neuroimaging
- Open Access
- 1 January 2025
- Published by Wiley in Depression and Anxiety
- Vol. 2025 (1)
Body Pain and Depressive Symptoms: Patterns and Associations in Middle‐Aged and Older Chinese Adults
Background: Depressive symptoms (DS) and body pain are prevalent conditions that significantly impact the quality of life of older adults, often co‐occurring with chronic diseases. This study aimed to explore the patterns of body pain characteristics and their association with DS among middle‐aged and older Chinese adults. Methods: This cross‐sectional study analysed data from 16,039 participants aged ≥45 years in the 2020 wave of the China Health and Retirement Longitudinal Study (CHARLS). DS were assessed using the 10‐item Centre for Epidemiologic Studies Depression Scale (CESD‐10). Body pain characteristics included pain severity and location. Multiple linear regression and mediation analyses were conducted to examine the relationships between chronic diseases, body pain, and DS. Results: Among participants, 5442 (33.9%) reported DS (CESD‐10 score ≥12). The DS group showed significantly higher body pain severity (2.66 ± 1.42 vs. 1.84 ± 1.11, p < 0.001) and more painful body parts (5.06 ± 3.87 vs. 3.68 ± 3.03, p < 0.001) compared to the non‐depressive group. Both pain severity and number of pain sites were independently associated with higher CESD‐10 scores. Mediation analysis revealed that body pain severity mediated 29.0% of the total effect between chronic diseases and DS. Conclusion: Body pain plays a significant mediating role in the relationship between chronic diseases and DS among middle‐aged and older Chinese adults. These findings emphasize the importance of implementing comprehensive healthcare approaches that integrate pain management with mental health support in primary care settings.
- 1 January 2025
- Published by Wiley in Depression and Anxiety
- Vol. 2025 (1)
Open AccessBody Pain and Depressive Symptoms: Patterns and Associations in Middle‐Aged and Older Chinese Adults
Background: Depressive symptoms (DS) and body pain are prevalent conditions that significantly impact the quality of life of older adults, often co‐occurring with chronic diseases. This study aimed to explore the patterns of body pain characteristics and their association with DS among middle‐aged and older Chinese adults. Methods: This cross‐sectional study analysed data from 16,039 participants aged ≥45 years in the 2020 wave of the China Health and Retirement Longitudinal Study (CHARLS). DS were assessed using the 10‐item Centre for Epidemiologic Studies Depression Scale (CESD‐10). Body pain characteristics included pain severity and location. Multiple linear regression and mediation analyses were conducted to examine the relationships between chronic diseases, body pain, and DS. Results: Among participants, 5442 (33.9%) reported DS (CESD‐10 score ≥12). The DS group showed significantly higher body pain severity (2.66 ± 1.42 vs. 1.84 ± 1.11, p < 0.001) and more painful body parts (5.06 ± 3.87 vs. 3.68 ± 3.03, p < 0.001) compared to the non‐depressive group. Both pain severity and number of pain sites were independently associated with higher CESD‐10 scores. Mediation analysis revealed that body pain severity mediated 29.0% of the total effect between chronic diseases and DS. Conclusion: Body pain plays a significant mediating role in the relationship between chronic diseases and DS among middle‐aged and older Chinese adults. These findings emphasize the importance of implementing comprehensive healthcare approaches that integrate pain management with mental health support in primary care settings.
- Open Access
- 25 October 2024
- Published by Association for Computing Machinery (ACM)
- p. 129-134
The PDS6Net, a sequence model based on state-space theory, is utilized to classifying Chronic Primary Pain and depression
- 25 October 2024
- Published by Association for Computing Machinery (ACM)
- p. 129-134
Open AccessThe PDS6Net, a sequence model based on state-space theory, is utilized to classifying Chronic Primary Pain and depression
- Open Access
- 1 July 2024
- Published by Taylor & Francis in Neuropsychiatric Disease and Treatment
- Vol. ume 20, 1465-1473
Comparison of the Efficacy Between Standard Measurement-Base Care (MBC) and Enhanced MBC for Major Depressive Disorder: A Pilot Study
Purpose: To validate the efficacy of enhanced measurement-based care against standard measurement-based care in patients with major depressive disorder. Patients and Methods: In this pilot study of an ongoing multicenter cluster randomized controlled trails, 160 patients diagnosed with major depressive disorder were enrolled from 2 mental health centers, with a plan to include 12 centers in total. One hundred patients engaged in a six-month evaluation using a technology-enhanced measurement-based care tool, including assessments of clinical symptoms, side effects, and functionality at baseline, two months, four months and six months. Simultaneously, the remaining 60 patients underwent standard paper-based measurement-based care, utilizing the same set of scales over the same six-month period, with assessments at the same time points. Results: Patients utilizing the enhanced measurement-based care tool demonstrated a significantly higher reduction rate in PHQ-9 scores compared to those using standard paper-based measurement-based care during the two-month follow-up. Additionally, a notable positive correlation was observed between the frequency of enhanced measurement-based care tool usage and the quality of life during the two-month follow-up. Conclusion: Enhanced measurement-based care has the effect of reducing depressive symptoms. Our study emphasized that using enhanced measurement-based care via smartphones is a feasible tool for patients with major depressive disorder. Our future study, including results from additional research centers, may further validate the effectiveness of enhanced measurement-based care.
- 1 July 2024
- Published by Taylor & Francis in Neuropsychiatric Disease and Treatment
- Vol. ume 20, 1465-1473
Open AccessComparison of the Efficacy Between Standard Measurement-Base Care (MBC) and Enhanced MBC for Major Depressive Disorder: A Pilot Study
Purpose: To validate the efficacy of enhanced measurement-based care against standard measurement-based care in patients with major depressive disorder. Patients and Methods: In this pilot study of an ongoing multicenter cluster randomized controlled trails, 160 patients diagnosed with major depressive disorder were enrolled from 2 mental health centers, with a plan to include 12 centers in total. One hundred patients engaged in a six-month evaluation using a technology-enhanced measurement-based care tool, including assessments of clinical symptoms, side effects, and functionality at baseline, two months, four months and six months. Simultaneously, the remaining 60 patients underwent standard paper-based measurement-based care, utilizing the same set of scales over the same six-month period, with assessments at the same time points. Results: Patients utilizing the enhanced measurement-based care tool demonstrated a significantly higher reduction rate in PHQ-9 scores compared to those using standard paper-based measurement-based care during the two-month follow-up. Additionally, a notable positive correlation was observed between the frequency of enhanced measurement-based care tool usage and the quality of life during the two-month follow-up. Conclusion: Enhanced measurement-based care has the effect of reducing depressive symptoms. Our study emphasized that using enhanced measurement-based care via smartphones is a feasible tool for patients with major depressive disorder. Our future study, including results from additional research centers, may further validate the effectiveness of enhanced measurement-based care.
- Open Access
- 5 November 2023
- Published by Elsevier in IBRO Neuroscience Reports
- Vol. 15, S253
CHARACTERIZATION OF SPONTANEOUS CALCIUM OSCILLATIONS AND THEIR ROLE IN MECHANO-ELECTRICAL COUPLING (MEC)
- 5 November 2023
- Published by Elsevier in IBRO Neuroscience Reports
- Vol. 15, S253
Open AccessCHARACTERIZATION OF SPONTANEOUS CALCIUM OSCILLATIONS AND THEIR ROLE IN MECHANO-ELECTRICAL COUPLING (MEC)